64th ASH Annual Meeting and Exposition: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational III

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Oral and Poster Abstracts
Oral

Research, apoptosis, Biological therapies, Antibody Therapy, Non-Biological therapies, Bispecific Antibody Therapy, Translational Research, Plasma Cell Disorders, bioinformatics, Combination therapy, Hemoglobinopathies, drug development, Diseases, immune mechanism, Therapies, immunology, Immunotherapy, Lymphoid Malignancies, computational biology, Biological Processes, Pharmacology, Technology and Procedures, molecular biology, omics technologies

New Orleans Theater C (Ernest N. Morial Convention Center)

Moderators:

Jo Caers, PhD, CHU de Liège and Marta Chesi, PhD, Department of Medicine, Mayo Clinic Arizona

Disclosures:

Chesi: Pfizer, Novartis.: Consultancy, Research Funding; Abcuro, Palleon Pharmaceuticals,, Pi Therapeutics.: Patents & Royalties: Genetically engineered mouse model of myeloma..

4:00 PM

349

Potent Pre-Clinical and Early Phase Clinical Activity of EP300/CBP Bromodomain Inhibitor CCS1477 in Multiple Myeloma

Luciano Nicosia, PhD¹^*, Nigel Brooks, PhD²^*, Fabio Amaral, PhD¹^*, Oliver Sinclair¹^*, Neil A Pegg²^*, William West, PhD, MSc, MBA²^*, Tomasz Knurowski, PhD, MD²^*, Kris Frese, PhD²^*, Karen Clegg, PhD²^*, James Cavet, PhD FRCP FRCPath³^*, Emma Searle^4,5^* and Tim C.P Somervaille, PhD FRCP FRCPath¹

¹Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom
²CellCentric Ltd, Cambridge, United Kingdom
³Haematology, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
⁴The University of Manchester, Manchester, United Kingdom
⁵The Christie Hospital, University of Manchester, Manchester, United Kingdom

4:15 PM

350

PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy Via Promoting Immunosuppressive Microenvironment

Tengteng Yu, MD¹^*, Mu Hao, PhD²^*, Hailin Chen, MD¹^*, Kenneth Wen¹^*, Tingjian Wang, MD³^*, Thomas C.M Smits⁴^*, Mehmet K. Samur, PhD⁴^*, Eugenio Morelli, MD⁵, Lijie Xing, MD⁶^*, Liang Lin, PhD¹^*, Jun Qi, PhD³^*, Gang An, MD²^*, Nikhil C Munshi, MD, PhD¹, Yu-Tzu Tai, PhD¹, Lugui Qiu² and Kenneth C. Anderson, MD¹

¹Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA
²State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
⁵Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
⁶Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

4:30 PM

351

Malignant Plasma Cell Derived Mitochondrial Damps Activate Macrophages Via Sting Signalling to Promote Myeloma Development

Aisha Jibril, BSc¹^*, Charlotte Hellmich, MBBChair^1,2^*, Jamie A Moore, BSc, MSc¹^*, Jayna J Mistry, PhD¹^*, Rebecca S Maynard, MSc¹^*, Katherine Hampton, MSc, BSc¹^*, Kristian M Bowles, MBBS, PhD^1,2 and Stuart A Rushworth, PhD¹

¹Norwich Medical School, University of East Anglia, Norwich, United Kingdom
²Department of Haematology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom

4:45 PM

352

A FAM46C-Dependent Molecular Circuit Modulates Antibody Synthesis and Proliferation in Plasma Cell Dyscrasias

Enrico Milan, PhD^1,2^*, Massimo Resnati³^*, Elena Riva³^*, Mario Nuvolone, MD, PhD⁴^* and Simone Cenci, MD^1,2

¹Vita-Salute San Raffaele University, Milano, Italy
²Laboratory of Age Related Diseases, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy
³Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milano, Italy
⁴Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Department of Molecular Medicine, University of Pavia, Pavia, Italy

5:00 PM

353

ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens

Maria Pihlgren, PhD¹^*, Olivia Hall, PhD¹^*, Laura Carretero, PhD¹^*, Carole Estoppey, PhD¹^*, Adam Drake, PhD¹^*, Daniela Pais, PhD¹^*, Jeremy Loyau, PhD¹^*, Jeremy Berret¹^*, Isabelle Gruber, PhD¹^*, Perrine Suere¹^*, Vincent Schnorhk¹^*, Emilie Nallet¹^*, Blandine Pouleau¹^*, Myriam Chimen, PhD¹^*, Julie Macoin¹^*, Elodie Stainnack¹^*, Thierry Monney, PhD¹^*, Aurore Delachat, PhD¹^*, Cyrille Dreyfus, PhD¹^*, Thomas Matthes, MD², Cyril Konto, MD³, Michael Dyson, PhD¹^*, Stanislas Blein, PhD¹^*, Lamine Mbow, PhD¹, Rebecca Wood, PhD¹^*, Ankita Srivastava, PhD¹^*, Eugene Zhukovsky, PhD¹ and Mario Perro, PhD¹^*

¹Ichnos Sciences Biotherapeutics SA, Lausanne, Switzerland
²Service d’Hématologie, Université de Genève, Onex, Switzerland
³Ichnos Sciences, New York

5:15 PM

354

Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells

Romanos Sklavenitis-Pistofidis, MD^1,2,3, Ting Wu, MS²^*, Mahshid Rahmat, PhD^1,2,3^*, Yoshinobu Konishi, MD, PhD^1,2,4^*, Elizabeth D. Lightbody, PhD^1,2,3, Michael Timonian, MD^1,2,3^*, Junko Tsuji, PhD²^*, Danielle T. Firer, BS²^*, Nicholas J. Haradhvala, PhD²^*, Cinnie Yentia Soekojo, MD^1,3, Xiyue Wang, MS³^*, Daniel Heilpern-Mallory, BS³^*, François Aguet, PhD²^*, Gad Getz, PhD^1,2,5^* and Irene Ghobrial, MD^1,2,3

¹Department of Medicine, Harvard Medical School, Boston, MA
²Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA
³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA
⁵Department of Pathology, Massachusetts General Hospital Cancer Center, Boston, MA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

651.O2.6 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational III